Completed PHASE3 INTERVENTIONAL 3-arm NCT00803335

The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse

The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse: A Randomized Control Trial

Sponsor: TriHealth Inc.

Conditions Pelvic Organ Prolapse Vaginal Atrophy

Interventions Vaginal conjugated estrogen cream 0.5gm Vaginal conjugated estrogen cream 1.0gm

Updated 6 times since 2017 Last updated: May 25, 2015 Started: Dec 31, 2008 Primary completion: May 31, 2011 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Pelvic Organ Prolapse and Vaginal Atrophy, this trial is completed. The trial is conducted by TriHealth Inc. and has accumulated 6 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Study Description(click to expand)

Subjective and objective vaginal health symptoms, validated pelvic floor questionnaires, cytology and histology will be analyzed.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

TriHealth Inc.

Data source: TriHealth Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States